ECE2018 Poster Presentations: Pituitary and Neuroendocrinology Pituitary - Clinical (101 abstracts)
The influence of levothyroxine (T4) treatment on metabolic parameters in central hypothyroidism (CH)
Milica Medic-Stojanoska 1, , Bojan Vukovic 1, , Ivana Bajkin 1, , Jovana Prodanovic 1, , Natasa Milosevic 2 , Stefan Stojanoski 2 , Jovanka Novakovic-Paro 1, & Nikola Curic 1,
1Clinical Center of Vojvodina, Novi Sad, Serbia; 2Medical faculty University of Novi Sad, Novi Sad, Serbia.
Introduction: L thyroxin treatment of CH is monitored by free T4 (fT4) which should be above mid normal range for the assay. It is not clear whether these doses are adequate for regulating the metabolic disturbances accompanying CH.
Aim: To determine whether T4 therapy leads to improvement of metabolic parameters in CH.
Materials and methods: This was a retrospective study. Study group comprised of 60 hypopituitary patients with CH, controls were 18 patients with hypopituitarism without CH. We analyzed fT4 and freeT3 (fT3), daily T4 dose, duration of CH, number of pituitary deficits, body mass index (BMI), arterial blood pressure, total cholesterol (TC), triglycerides, HDL, LDL, fasting blood glucose (FBG) and insulinemia, HOMA IR, and spine and hip bone mineral density (BMD).
Results: fT4 was normal in both groups (13.55±2.72 vs. 13.54±1.86 pmol/l). FT3 was normal but significantly lower in CH group (3.76±0.84 vs. 4.45±1.16 pmol/l; P< 0.028). Average dose of T4 was 1.26±0.54 μg/kg/body weight. Duration of CH was 10.36±11.69 years. Number of pituitary deficits was significantly higher in CH group (P< 0.001). Triglycerides were elevated in the CH group, but the difference was insignificant (1.91±1.07 vs. 1.45±1.45±0.86 mmol/l, P=0.10). HDL was low in CH group and difference was significant (1.07±0.32 vs. 1.52±0.54, P<0.001). Other parameters were normal and did not differ. FT4 was significantly positively correlated with HDL and negatively with hip BMD (P< 0.05; P<0.01; P< 0.002). FT3 was significantly negatively correlated with FBG (P<0.02). T4 dose was significantly positively correlated with BMI, negatively with spine and hip BMD (P< 0.04; P<0.008; P<0.004; P<0.007). Duration of CH was significantly negatively correlated with spine and hip BMD (P<0.03; P< 0.004; P<0.001).
Conclusion: Apart from fT4 metabolic parameters should be taken into account when treating CH.
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more